scholarly journals Comparative immunogenicity of fowl cholera vaccine in Jinding ducks

2014 ◽  
Vol 30 (2) ◽  
pp. 41-45 ◽  
Author(s):  
S Sultana ◽  
S Saha ◽  
MM Amin

This study compared the immunogenicity of alum-precipitated formalin-killed fowl cholera vaccines (BAU-FCV and LRI-FCV) in Jinding ducks. The ducks were divided into three groups (A = 14, B = 14, C = 12). Group A was inoculated with BAU- FCV 0.5 mL and group B with LRI- FCV 1.0 mL intramuscularly (im) at the age of six weeks and group C served as unvaccinated control. Booster vaccination was administered similarly at 11 weeks of age in groups A and B. Challenge infection was given to all birds two weeks after booster vaccination. Passive Haemagglutination Assay (PHA) antibody titres in group A were 59.4 ± 4.6 21 days after primary vaccination, 137.1 ± 21.8 15 days after booster vaccination, 100.6 ± 12.9 21 days after booster vaccination, and 256.0 ± 48.4 15 days after challenge. In group B, titres were 50.3 ± 6.5, 118.9 ± 9.1, 91.4 ± 12.9, 237.7 ± 51.7, respectively, whereas titres in group C remained at ?4.0 ± 0.0. The antibody titres were insignificant when compared between pre-vaccination and 21 days after primary vaccination in both vaccinated groups (A and B). PHA antibody titres of groups A were significantly (P < 0.0001) increased at 15 days after booster and in case of group B the antibody titres were insignificant. At 15 days after challenge the antibody titres were highly significant in both groups (A and B). There was no significant difference between the two vaccinated groups. Following challenge infection with virulent Pasteurella multocida 88.9% of birds vaccinated with BAU-FCV, and 77.8% of birds vaccinated with LRI-FCV survived, while all unvaccinated birds died. Both vaccines were safe and effective. DOI: http://dx.doi.org/10.3329/bvet.v30i2.18253 Bangl. vet. 2013. Vol. 30, No. 2, 41-45

2019 ◽  
Author(s):  
S. Akter ◽  
C. N. Shampa ◽  
M. A. Islam ◽  
A. U. Alam ◽  
M. Hadiuzzaman ◽  
...  

Background: Duck cholera is an acute, fatal, septicemic disease of domestic ducks which is responsible for significant loss in duck population. The present study was conducted to compare the immunogenicity of two formalin killed fowl cholera vaccines (BAU-FCV and DLS-FCV) in indigenous ducks. Methods: The experimental ducks were divided into three groups (A=15, B=15 and C =10 ducks) of which birds of Group A and Group B were inoculated with 0.5 ml of BAU-FCV and DLS-FCV, respectively through subcutaneous route at the age of 10 weeks whereas ducks of group C were kept as unvaccinated control. Booster vaccination was done with same dose and route at 14 weeks of age. Challenge infection was conducted after 2 weeks of booster vaccination. Results: The mean PHA antibody titres on 15 days post vaccination (DPPV), 28 DPPV, 15 days postsecondary vaccination (DPSV), 28 DPSV and 15 days post challenge were 25.60 ± 3.92, 51.20 ± 7.84, 89.60 ± 15.68, 166.40 ± 38.40 and 204.80 ± 31.35, respectively in ducks of Group A whereas, the mean antibody titres in ducks of Group B were 25.60 ± 3.92, 44.80 ± 7.84, 64.00 ± 7.53,102.40 ± 15.68 and 179.20 ± 31.35 at 15 DPPV, 28 DPPV, 15 DPSV, 28 DPSV and 15 days after challenge, respectively. In this investigation, slightly higher immune responses were observed in ducks of Group A vaccinated with BAU-FCV compare to ducks of Group B vaccinated with DLS-FCV. Birds of both vaccinated groups conferred 100% protection against challenge infection with virulent Pasteurella multocida whereas, 100% mortality was observed in control ducks after challenge. Conclusion: Both vaccines were found to be safe and effective for the vaccination of indigenous ducks against duck cholera.


2018 ◽  
Vol 5 (2) ◽  
pp. 193-199
Author(s):  
Chamak Nahar Shampa ◽  
Suma Akter ◽  
Sukumar Saha ◽  
Md Hadiuzzaman ◽  
Azhar Ul Alam ◽  
...  

The present study was conducted to determine the immune response induced in indigenous chicken produced against BAU-FC and DLS-FC vaccines with their efficacy study against Pasteurella multocida. A total of forty (40) chickens were selected and divided into Group A (15), Group B (15) and Group C (10). Group A and B were vaccinated with BAU-FCV and DLS-FCV, respectively at the dose rate of 0.5 ml through SC at six weeks of age followed by boostering at 10 weeks of age while Group C was kept as unvaccinated control. Sera samples were collected after primary and booster vaccination and antibody titre was determined by Passive hemagglutination (PHA) test. The mean PHA titres recorded at 4 weeks after primary vaccination was 51.20 ± 7.84 in birds of group A and 38.40 ± 6.40 in birds of Group B. After booster vaccination, mean PHA titer was found 140.80 ± 31.35 at 16 weeks of age in case of BAU-FC vaccinated group and 115.20 ± 12.80 in case of DLS-FC vaccinated group. The mean PHA titer was 204.80 ± 31.35 and 179.20 ± 31.35 at 19 weeks of age in birds of BAU-FC and DLS-FC vaccinated group, respectively. Birds of all groups were challenged with virulent P. multocida at 17 weeks of age. It was observed that vaccinated chickens showed maximal resistance (100%) following challenge with virulent whereas unvaccinated control birds failed to resist the challenge infection. It can be assumed from the findings of present research work that both BAU-FCV and DLS-FCV are able to protect indigenous chicken from the outbreak of avian pasteurellosis and BAU-FV vaccine showed relatively higher immuno-protective titre than that of DLS-FC vaccine.Res. Agric., Livest. Fish.5(2): 193-199, August 2018


2015 ◽  
Vol 13 (1) ◽  
pp. 5-9
Author(s):  
MAS Bag ◽  
MM Amin ◽  
MB Rahman ◽  
YA Arafat ◽  
M Salim ◽  
...  

The research work was performed to investigate the immunogenicity of Salmonella vaccine produced at LPVRPC, BAU Mymensingh. The vaccination was performed at the Phenix Hatchery Ltd. Gazipur in Hy-sex brown and HY-sex white chicken designated as group A and group B respectively. Group A and B were subdivided into A1, A2, A3, B1, B2 and B3 groups containing eight birds each. Group C was maintained as unvaccinated control. Birds were immunized following schedule of the LPVRPC. Each bird was vaccinated SC at six weeks of age followed by a subsequent booster dose after 45 days. After four weeks of primary vaccination the mean PHA antibody titres were 96.00±34.21 in group A1 and 96.00±34.21 in B1 group. Prebooster vaccination the mean PHA antibody titres were 88.00±33.12 in group A2 and 88.00±33.12 in B2 group. At four weeks of booster vaccination the mean PHA antibody titres were 104.00±33.12 in group A3 and 104.00±33.12 in B3 group. The mean ± PHA antibody titre in chickens of group C was ? 4.0±0.00. Salmonella vaccine prepared at (LPVRPC) Department of Microbiology and Hygiene, BAU induces satisfactory level of antibody in chickens determined by PHA test conducted in an on-farm study of layer chickens.DOI: http://dx.doi.org/10.3329/bjvm.v13i1.23705Bangl. J. Vet. Med. (2015). 13 (1): 5-9


1970 ◽  
Vol 7 (2) ◽  
pp. 295-299
Author(s):  
MZ Uddin ◽  
MSR Khan ◽  
F Begum ◽  
MA Mannan

The study was performed with a view to isolate and identify a virulent strain of S. gallinarum and determine the purity, safety and efficacy of BIO-TYPHOID® vaccine. A total of 40 backyard layer chicken were used for this study where Group A was used for experimental vaccination, Group B kept as control and Group C was used for calculating virulent S. gallinarum challenge dose. Primary and secondary vaccination was carried out at 40 days and 110 days of age, respectively. Blood samples were collected to obtain the sera after vaccination from both vaccinated and unvaccinated control group and antibody titres were determined by Microplate agglutination test. The antibody titre increased in primary vaccination up to days 56 days post vaccination (DPV) and then decreased gradually. The highest antibody titre (Mean ± SE) 384.00 ± 42.67 was obtained at 91 DPV (21 days later of secondary vaccination) and maintained up to 98 DPV. Safety test was done by inoculating mice and purity test of the vaccine was done by inoculating on to Blood Agar media. The efficacy of BIO-TYPHOID® vaccine was recorded as 90% which was determined by challenge infection with 0.1 ml of 5x105 CFU virulent S. gallinarum. Results of this study revealed successful protections by BIO-TYPHOID® vaccine. Keywords: BIO-TYPHOID® vaccine; Chicken; Efficacy; Fowl Typhoid DOI: 10.3329/jbau.v7i2.4737 J. Bangladesh Agril. Univ. 7(2): 295-299, 2009


2021 ◽  
Vol 8 (1) ◽  
pp. 117-124
Author(s):  
Mashuda Akter ◽  
Md Mosaraf Hossain ◽  
Md Kamrul Hassan ◽  
Ravi Yadav ◽  
Fahima Morsheda ◽  
...  

An experiment was conducted to investigate the immune response induced in chickens by capsular extract of Pasteurella multocida isolated from rats wandering in and around the poultry farms. The rat isolate of P. multocida was isolated and identified by cultural, morphological, and biochemical characteristics, followed by capsular extract preparation and experimental vaccine development. The isolated P. multocida was found Gram-negative, non-motile, non-spore forming rod occurring singly or pains and occasionally as chains or filaments in Gram’s-staining method. The isolates consistently produced acid from dextrose, sucrose and mannitol but not fermented maltose or lactose. The Capsular antigen was extracted and confirmed by acriflavine test. Finally, experimental fowl cholera vaccine was prepared. Primary vaccination was performed at the dose rate of 5.6×107 CFU/ml through intramuscular and subcutaneous routes in birds of group A (10 birds) and group B (10 birds) and group C (10 birds) were control birds. Secondary vaccination was similarly performed after 15 days of primary vaccination in groups A and B. The levels of pre-vaccination and post-vaccination sera were determined by passive haemagglutination test. The passive haemagglutination antibody titre was recorded on 15 and 35 days of post vaccination in groups A and B. It was demonstrated that experimental capsular extract fowl cholera vaccine conferred 100% protection (p<0.01) against challenge infection and found to be safe. It could be suggested that after thorough field trial, the experimentally prepared capsular extract FC vaccine using rat isolate of P. multocida may be used side by side with conventional FC vaccine. Res. Agric., Livest. Fish.8(1): 117-124, April 2021


2013 ◽  
Vol 2 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Samina Ievy ◽  
Mohammad Ferdousur Rahman Khan ◽  
Md Ariful Islam ◽  
Md Bahanur Rahman

The research work was performed for the isolation and identification of Pasteurella multocida from field cases, preparation of oil adjuvanted vaccine from isolated strain and determination of its efficacy. Samples were collected from suspected dead birds of three poultry farms of Bangladesh (Code name: M and R). The P. multocida isolates were Gram negative, non-motile, non- spore forming rod occurring singly or pairs and occasionally as chains or filaments. Biochemically P. multocida ferment basic sugar and consistently produced acid except from maltose and lactose. After isolation formalin killed oil adjuvanted Fowl cholera vaccine was prepared in Laboratory of the Department of Microbiology and Hygiene, BAU and this experimental vaccine (3.2x108 CFU/ml) was administered in nine weeks old White Leg Horn chickens at the different dose rate through intramuscular (IM) route in each selected group A (1ml alum precipitated vaccine), B (0.5ml alum precipitated vaccine), C (1ml oil adjuvanted vaccine) and D (0.5ml oil adjuvanted vaccine). Pre-vaccinated sera were collected from all groups of birds. The mean of Passive Hemagglutination (PHA) titers of post-vaccination were 51±17.8, 76.8±17, 89.6±17, and 115±17.81 in group A, B, C and D respectively which consist of 5 birds in each. The vaccine produced better immune response when boostering with the similar dose and route at 15 days after primary vaccination. The mean PHA titers were higher at group D than other groups after boostering. Challenge infection was conducted on all the vaccinated and control group (n=5) of birds after 15 days of vaccination which protect 93.75% of birds and the PHA titers from different groups analyzed to determine the protective capacity of vaccinated chickens against challenge exposure. It was demonstrated that experimental oil adjuvanted fowl cholera vaccine with 0.5ml dose produce higher immune response against challenge infection and found to be safe. Microbes and Health, June 2013, 2(1): 1-4DOI: http://dx.doi.org/10.3329/mh.v2i1.17253


2013 ◽  
Vol 1 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Sreebas Chandra Sarkar ◽  
Sukumar Saha ◽  
Md Mansurul Amin ◽  
Md Golzar Hossain

The study was conducted to investigate the efficacy of Baby chick Ranikhet Disease Vaccine (BCRDV) and Ranikhet Disease Vaccine (RDV) produced by the Livestock Research Institute (LRI), Mohakhali, Dhaka. For this experiment, 100 day-old-chick was purchased from Phinex Hatchery Ltd., Gazipur. The chicks (n=100) were divided into two groups. In group A (n=50), vaccination was performed twice with BCRDV at 2 and 21 days of age through intraocular route (i/o) followed by once with RDV at 60-day of age through intramuscular (i/m) route. Group B (n=50) was kept as unvaccinated control. The immunogenicity of the vaccine was evaluated by measuring the serum HI antibody titers at 1-, 20-, 36-, and 76-day of age, while the vaccine efficacy was examined by a challenge infection experiment with a velogenic field isolate of NDV as well as passive protection test. It was observed that the maternal antibody titers of the unvaccinated control group B gradually declined from day 1 to day 76 of age. Conversely, after primary and secondary vaccination with BCRDV, the levels of serum HI titer slightly increased in vaccinated group A compared with those in control group B. Finally administration of RDV resulted in a sharp increase in HI titer, leading to protection from challenge infection with virulent field virus as well as passive protection test. These results clearly demonstrated that a prime-booster immunization with BCRDV and RDV, both produced by LRI, is effective to protect chicken against Newcastle disease (ND).DOI: http://dx.doi.org/10.3329/mh.v1i1.13706 Microbes and Health Vol.1(1) June 2012 pp.9-13


2020 ◽  
Vol 57 (4) ◽  
Author(s):  
Wafaa Abd El-Ghany ◽  
Hanan Ali Ahmed ◽  
Ali Zaher Qandoos ◽  
Mohamed Abd El-Rahman Bosila Bosila

This study was carried out to evaluate the efficacy of vaccination of layer chickens with inactivated FC bacterin prepared from local Egyptian strains of Pasteurella multocida (P. multocida). A total of 200 layer chickens were divided into 5 equal groups, 40 for each. At the age of 6 weeks, chickens in groups (A) and (B) were vaccinated with P. multocida serotypes A:1 and A:3, respectively, booster doses were given after 3 weeks (9 weeks old) and challenge was done with virulent serotypes A:1 and A:3 at 2 weeks later (11 weeks old). Chickens in groups (C) and (D) were not vaccinated, only challenged with P. multocida serotype A:1 and A:3, respectively. Birds in group (E) were kept as non-vaccinated and non-challenged. Blood samples were collected weekly from all groups for humoral immune response. All the birds were kept under observation for signs, mortalities, lesions and re-isolation of challenging organism and for histopathological examination. Results of the mean Enzyme Linked Immuno-Sorbent Assay (ELISA) revealed that the highest level was at 5 weeks post vaccination as the titers reached to 3970 in group (A) and 3905 in group (B). The clinical signs, mortality rate and lesions were mild in the vaccinated birds while severe lesions were in non-vaccinated and challenged birds. The protection rates were 85 % and 80 % in groups (A) and (B); respectively, while 10 % and 20 % in groups (C) and (D); respectively. The re-isolation rates of P. multocida after challenge were 95 % and 90 % in non-vaccinated-challenged birds with P. multocida serotypes A:1 and A:3; respectively, while they were 25 % and 15 % in vaccinated-challenged groups with P. multocida serotypes A:1 and A:3; respectively. Histopathological examination of P. multocida vaccinated-challenged birds revealed mild to no microscopic lesions when compared with non-vaccinated challenged chickens. In conclusion, the prepared FC inactivated bacterin from the local Egyptian predominant P. multocida serovars proved efficacy and protection of layer chickens. Key words: Pasteurella multocida; chickens; immunization; protection; Egypt UČINKOVITOST CEPLJENJA KOKOŠI NESNIC Z INAKTIVIRANO BAKTERIJO KOLERE PERJADI, PRIPRAVLJENE IZ LOKALNIH EGIPTOVSKIH SEVOV BAKTERIJE Pasteurella multocida Povzetek: Raziskava je bila izvedena z namenom ocenitve učinkovitosti cepljenja kokoši nesnic z inaktivirano bakterijo FC, pripravljeno iz lokalnih egiptovskih sevov bakterije Pasteurella multocida (P. multocida). Skupno 200 kokoši nesnic je bilo razdeljenih v 5 enakih skupin. V vsaki skupini je bilo 40 kokoši. Pri 6 tednih smo kokoši v skupinah A in B cepili s serotipoma P. multocida A:1 in A:3, po 3 tednih, ko so bile živali stare 9 tednov, so dobile poživitvene doze cepiva. Po dveh tednih (v starosti 11 tednov) so bile kokoši okužene z virulentnima serotipoma A:1 in A:3. Piščanci v skupinah C in D niso bili cepljeni temveč samo okuženi s serotipoma A:1 in A:3. Kokoši v skupini E niso bile niti cepljene, niti okužene. Vzorci krvi so bili odvzeti pri vseh skupinah tedensko za preverjanje humoralnega imunskega odziva. Vse kokoši smo stalno opazovali in beležili prisotnost bolezenskih znakov, različnih ran in umiranje kokoši. Pri poginulih kokoših smo osamili bakterije ter opravili histopatološki pregled. Rezultati encimsko-imunskega testa (ELISA) so pokazali da je bila najvišja stopnja zaščite dosežena 5 tednov po cepljenju, saj so titri dosegli 3970 v skupini A in 3905 v skupini B. Klinični znaki, stopnja umrljivosti in rane so bili pri cepljenih kokoših blagi, hude rane pa so bile vidne pri necepljenih in okuženih kokoših. Stopnja zaščite je bila v skupinah A in B 85- oziroma 80-odstotna, v skupinah C in D pa 10- oziroma 20-odstotna. Stopnje ponovne izolacije P. multocida po okužbi so bile 90 in 95 odstotkov pri kokoših, ki niso bile cepljene, medtem, ko so bile v skupinah, ki so bile okužene s P. multocida serotipa A:1 in A:3 15- in 25-odstotkov. Histopatološki pregled cepljenih in okuženih kokoši je pokazal popolno odsotnost ali prisotnost blagih mikroskopskih poškodb, medtem ko so imele necepljene okužene kokoši bolj obsežne histopatološke poškodbe. Pripravljena inaktivirana bakterija FC iz lokalnih egiptovskih prevladujočih serovarov P. multocide se je izkazala za učinkovito zaščito kokoši nesnic.Ključne besede: Pasteurella multocida; kokoši; imunizacija; zaščita; Egipt


2012 ◽  
Vol 3 (1) ◽  
pp. 07-12
Author(s):  
MT Islam ◽  
MA Samad ◽  
MI Hossain

The research work was carried out to determine the immunogenic response with efficacy of six commercial Gumboro, vaccines (Nobilis® Gumboro D78 and Nobilis® Gumboro 228E, Intervet, The Netherlands; Bur-706®, Merial, France; TAD Gumboro vac® and TAD Gumboro vac forte®, Lohmann Animal Health, Germany; BursaplexTM, Merial Select, Inc. Gainesville, USA) under experimental condition in broiler chickens during the period from November 2002 to May 2003. The chickens of two groups were vaccinated with Nobilis® Gumboro D78 and Nobilis® Gumboro 228E at 14 days of age with a booster dose at 21 days of age and were challenged at 40 days of age with vvIBDV. TAD Gumboro vac® and TAD Gumboro vac forte® were inoculated into the two groups of chickens at 14 and 28 days of age and the chickens were challenged at 35 days of age with vvIBDV. Bur-706® vaccine was given to the chickens of another group at one-day-old and 14 days of age and the chickens were challenged at 28 days of age. One group of chickens was vaccinated with Bursaplex™ vaccine at 1-day-old with no booster dose and was challenged at 21 days of age. The percentage of protection in birds receiving Nobilis® Gumboro D78 and Nobilis® Gumboro 228E vaccines by intraocular route was 92.30 and 96.29 respectively, whereas the percentages of protection in birds receiving TAD Gumboro vac®, TAD Gumboro, vac forte® and Bur-706® vaccines were 95.65, 100 and 95.83 respectively. BursaplxTM provided 100% protection against challenge with vvIBDV. Chickens vaccinated with Nobilis® Gumboro D78, Nobilis® Gumboro 228E, TAD Gumboro vac®, and Bur-706®, showed significant (p < 0.05, p < 0.01) decrease in ELISA antibody titre up to the day of challenge infection. BursaplexTM vaccinated group also showed significant decrease in ELISA antibody titre by 7 days (p < 0.05) and by 14 and 21 days (p < 0.01) after primary vaccination. In case of TAD Gumboro vac forte®, 7 days (839 ± 219.34) and 14 days (258 ± 44.80) after primary vaccination, the ELISA antibody titre significantly (p < 0.01) decreased but 7 days after booster vaccination, the ELISA antibody titre significantly (p < 0.01) increased (1299 ± 37.51). All the control sera revealed significant (p < 0.01) decrease of ELISA antibody titre up to day of challenge infection. There was an insignificant increase in ELISA antibody titre 7 days after booster vaccination in case of unvaccinated control groups for TAD Gumboro vac® and TAD Gumboro vac forte® only. Nobilis® Gumboro D78, TAD Gumboro vac® and Bur-706® vaccinated groups revealed significant (p < 0.01) increase of ELISA antibody titre 7 days post-challenge while Nobilis® Gumboro 228E and BursaplexTM vaccinated groups showed significant (p < 0.05) increase of antibody titre after 7 days of challenge. Insignificant increase of antibody titre was recorded in TAD Gumboro vac forte® vaccinated group. It may be concluded that TAD Gumboro vac forte® (intermediate plus) and BursaplexTM (Merial Select, Inc. Gainesville, USA) can be used to immunize the broiler birds sufficiently against IBD. However, it is necessary to estimate the optimum vaccination timing, i.e., to determine when maternal antibodies in chicks will decline to levels that the vaccines can overcome.


1970 ◽  
Vol 2 (2) ◽  
pp. 117-119 ◽  
Author(s):  
MT Hossain ◽  
MA Islam ◽  
S Akter ◽  
M Sadekuzzaman ◽  
MA Islam ◽  
...  

Effect of dose and time of vaccination on immune response of duck plague vaccine in 90 (45 of 18-day-old and 45 of 35-day-old) Jinding ducklings was studied during the period from October 2002 to March 2003. Each of both age group (18-day-old and 35-day-old) was divided into three groups as A, B, C and D, E, F respectively, consisting of 15 ducklings in each. Each duckling of groups A and B was primarily vaccinated with 0.25 ml and 0.5 ml of duck plague vaccine (LRI, Mohakhali) intramuscularly at 18 days old respectively and could not be boosted due to the death of all the ducklings of both groups within 20 days of primary vaccination. Each duckling of group D and E received 0.5 ml and 1.0 ml of duck plague vaccine (LRI, Mohakhali) intramuscularly at 35 days old respectively and ducks of both the groups boosted with 1.0 ml of vaccine 5 months after primary vaccination. Groups C and F served as unvaccinated control. 14 days after booster vaccination ducks of group D, E and F were challenged with the virulent field isolate of duck plague virus @ 1.0 ml / duck IM (104 EID50 / dose). The ducklings of group D that were vaccinated primarily at 35 days old with 0.5 ml and boosted after 5 months with 1.0 ml of duck plague vaccine had significantly (p< 0.01) higher PHA titres after 2 weeks of primary vaccination (38.4 ± 6.4), booster vaccination (153.6 ± 25.6) and challenge infection (281.6 ± 62.71) in comparison to control group (≤4, ≤4 and 20.0 ± 2.3 respectively) and all the ducks survived (100%) after challenge. The ducklings of group E that were vaccinated primarily at 35 days old and boosted after 5 months of primary vaccination with 1.0 ml of duck plague vaccine had also significantly (p< 0.01) higher PHA titres after two weeks of booster vaccination (76.8 ± 12.8) and challenge infection (153.6 ± 25.6) in comparison to control group, but only 8 (53.3%) ducks could protect the challenge infection with virulent duck plague virus. It may be concluded that ducklings below 30 days of age should not be vaccinated with duck plague vaccine. It also may be proposed that primary vaccination at 35 days old with duck plague vaccine (LRI, Mohakhali) @ 0.5 ml / duckling and booster vaccination after 5 months of primary vaccination @ 1.0 ml could be practiced for better immune response against duck plague.Key words: effect; dose; age; immune response; duck plague vaccine; ducksdoi: 10.3329/bjvm.v2i2.2542Bangl. J. Vet. Med. (2004). 2 (2): 117-119


Sign in / Sign up

Export Citation Format

Share Document